What this study is
The clinical trial is a prospective randomized control trial of a group of patients undergoing surgical management of common orthopedic pathologies including fractures of the upper extremity and shoulder arthroplasty; arthritis surgeries (ex. carpometacarpal arthroplasty), release of compressive neuropathies (ex. carpal tunnel surgery), tendon procedures (ex. tendon repair), patients undergoing total hip arthroplasty for osteoarthritis of the hip or total knee arthroplasty for osteoarthritis of the knee.
Patients will be assigned randomly to one of two treatment arms: (1) single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care) or (2) single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course (Active Group).
The purpose of this study is to study the efficacy of a post-operative course of glucocorticoids (GCs like Methylprednisolone) on pain, nausea and range of motion after surgical management of common orthopedic upper extremity pathologies, including fractures of the upper extremity and shoulder arthroplasty and patients undergoing total hip arthroplasty for osteoarthritis of the hip or total knee arthroplasty for osteoarthritis of the knee.
What's being tested
- 10 mg IV dexamethasone & 6 day oral methylprednisolone taper
Intervention · DRUG
Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day. Drug:10 mg intravenous (IV) dexamethasone
- 10 mg IV dexamethasone
Intervention · OTHER
Drug:10 mg intravenous (IV) dexamethasone
Study details
- Sponsor
- Emory University
- Conditions
- Orthopedic Surgeries
- Enrolling
- 500 people
- Starts
- 2018-09-07
- Est. completion
- 2029-01
- Design
- Open-label, randomized, parallel groups, Phase 4
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 95 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Patients of Emory Hand Surgeons undergoing surgery for an upper extremity fracture who are willing to participate in the study will be included in the study (Including American Orthopedic(AO) and American Orthopaedic Trauma Association (OTA) AO/OTA Classification 1, 2, and 7 +/- Type A, B, C).
- Patients of Emory Hand Surgeons undergoing Total Shoulder Arthroplasty or Reverse Shoulder Arthroplasty who are willing to participate in the study will be included in the study (Walsh Classification A-D).
- Patients of Emory Hand Surgeons undergoing surgery for upper extremity arthritis (ex. carpometacarpal arthroplasty)
- Patients of Emory Hand Surgeons undergoing release for upper extremity compressive neuropathies (ex. carpal tunnel surgery)
- Patients of Emory Hand Surgeons undergoing procedures for upper extremity tendon pathologies (ex. tendon repair)
- Patients undergoing total hip arthroplasty for osteoarthritis of the hip
- Patients undergoing total knee arthroplasty for osteoarthritis of the knee
- Between the ages of 18 years and 95 years.
- Patients willing and able to provide written and informed consent
You can't join if
- Patients with concurrent and significant injuries to other bones or organs.
- Patients with local infections.
- Patients who are minors, vulnerable subjects, or who are not willing to consent to participate in the study.
- History of alcohol or medical abuse, allergies to glucocorticoids, daily use of glucocorticoids or chronic opioid use prior to the injury (morphine, fentanyl, hydromorphone, ketobemidone, methadone, nico morphine, oxycodone, and meperidine), history of severe heart disease ( New York Heart Association (NYHA 2)), renal failure, or liver dysfunction, active peptic ulcer disease, diabetic neuropathy, rheumatoid arthritis, and neurological or psychiatric diseases, potentially influencing pain perception.
- Women who are pregnant
- Patients with pre-existing immune suppression, where further immune suppression with GCs could warrant unwarranted or unneeded risk.
- Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (3)
3 openEmory Clinic A, Clifton Road Clinic
Atlanta, Georgia, United States
21 Ortho Lane
Atlanta, Georgia, United States
Emory Healthcare Orthopaedics and Spine Center
Atlanta, Georgia, United States
Study team
Sponsor
Emory University
Study ID IRB00104310
Principal investigator
Michael Gottschalk, MD
Emory University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.